What is the address of PHARMAWATCH?

The registered office of PHARMAWATCH is located at Hondsstraat 19 box 4, 3700 Tongeren-Borgloon.

Is PHARMAWATCH still active?

Yes. According to the CBE (17 September 2026) PHARMAWATCH is active, legal situation “Normale toestand”, started on 27 January 2014.

Is PHARMAWATCH registered on Peppol?

Yes, PHARMAWATCH is registered on the Peppol network with ID 0208:0544921155.

What is the enterprise number of PHARMAWATCH?

The enterprise number of PHARMAWATCH is BE0544921155.

When was PHARMAWATCH founded?

PHARMAWATCH was founded on 27 January 2014.

Who are the directors of PHARMAWATCH?

According to the 2025 annual accounts, the directors of PHARMAWATCH are: Didier Laeckmann.

Is PHARMAWATCH a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 January 2014; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMAWATCH make in 2025?

PHARMAWATCH recorded a loss after taxes of € 30,674 in financial year 2025.

What is the revenue of PHARMAWATCH?

As a small company, PHARMAWATCH is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -25,552.

PHARMAWATCH (Private Limited) - Tongeren-Borgloon

Q: What does PHARMAWATCH do?

PHARMAWATCH is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 27 January 2014.

Dossier PHARMAWATCH, printed on 17 September 2026 from databakkes.be/en/0544921155/pharmawatch. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMAWATCH from Tongeren-Borgloon, company number BE0544921155, closed financial year 2025 with a result of € -30,674 after tax. For that financial year PHARMAWATCH recorded a gross margin of € -25,552 and equity of € 292,868. Compared with financial year 2024, the result moved from € 35,033 to € -30,674. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Healthy

€ 292,868

▼ 9% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -30,674

▼ still € 35,033 profit in 2024

Profit after tax over the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 286,668.

People and assets in 2025

Vehicles and equipment

€ 17,667

▼ 50% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 1 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 33,493

▲ 3% vs 2024

€ 14,598 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.

Owed to suppliers

€ 25,303

▼ 56% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 4,200

▼ 45% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 82,769 Gross margin 2022: € 82,769 First fiscal year in the series	€ 66,863 Gross margin 2023: € 66,863 ▼ 19% vs 2022 (€ 82,769) Unfavourable step	€ 63,880 Gross margin 2024: € 63,880 ▼ 4% vs 2023 (€ 66,863) Unfavourable step	€ -25,552 Gross margin 2025: € -25,552 ▼ € 89,432 vs 2024 (€ 63,880) Unfavourable step	▼ € 89,432
Profit after taxes	€ 61,886 Profit after taxes 2022: € 61,886 First fiscal year in the series	€ 43,964 Profit after taxes 2023: € 43,964 ▼ 29% vs 2022 (€ 61,886) Unfavourable step	€ 35,033 Profit after taxes 2024: € 35,033 ▼ 20% vs 2023 (€ 43,964) Unfavourable step	€ -30,674 Profit after taxes 2025: € -30,674 ▼ € 65,707 vs 2024 (€ 35,033) Unfavourable step	▼ € 65,707
Equity	€ 244,545 Equity 2022: € 244,545 First fiscal year in the series	€ 288,508 Equity 2023: € 288,508 ▲ 18% vs 2022 (€ 244,545) Favourable step	€ 323,542 Equity 2024: € 323,542 ▲ 12% vs 2023 (€ 288,508) Favourable step	€ 292,868 Equity 2025: € 292,868 ▼ 9% vs 2024 (€ 323,542) Unfavourable step	▼ 9%
Total debts	€ 186,427 Total debts 2022: € 186,427 First fiscal year in the series	€ 81,824 Total debts 2023: € 81,824 ▼ 56% vs 2022 (€ 186,427) Favourable step	€ 97,330 Total debts 2024: € 97,330 ▲ 19% vs 2023 (€ 81,824) Unfavourable step	€ 62,996 Total debts 2025: € 62,996 ▼ 35% vs 2024 (€ 97,330) Favourable step	▼ 35%
Cash	€ 19,705 Cash 2022: € 19,705 First fiscal year in the series	€ 2,065 Cash 2023: € 2,065 ▼ 90% vs 2022 (€ 19,705) Unfavourable step	€ 8,122 Cash 2024: € 8,122 ▲ 293% vs 2023 (€ 2,065) Favourable step	-
Retained profit	€ 238,345 Retained profit 2022: € 238,345 First fiscal year in the series	€ 282,308 Retained profit 2023: € 282,308 ▲ 18% vs 2022 (€ 238,345) Favourable step	€ 317,342 Retained profit 2024: € 317,342 ▲ 12% vs 2023 (€ 282,308) Favourable step	€ 286,668 Retained profit 2025: € 286,668 ▼ 10% vs 2024 (€ 317,342) Unfavourable step	▼ 10%
Bank debt	€ 63,148 Bank debt 2022: € 63,148 First fiscal year in the series	€ 46,054 Bank debt 2023: € 46,054 ▼ 27% vs 2022 (€ 63,148) Favourable step	€ 32,429 Bank debt 2024: € 32,429 ▼ 30% vs 2023 (€ 46,054) Favourable step	€ 33,493 Bank debt 2025: € 33,493 ▲ 3% vs 2024 (€ 32,429) Unfavourable step	▲ 3%
Balance sheet total	€ 430,972 Balance sheet total 2022: € 430,972 First fiscal year in the series	€ 370,332 Balance sheet total 2023: € 370,332 ▼ 14% vs 2022 (€ 430,972) Unchanged	€ 420,872 Balance sheet total 2024: € 420,872 ▲ 14% vs 2023 (€ 370,332) Unchanged	€ 355,864 Balance sheet total 2025: € 355,864 ▼ 15% vs 2024 (€ 420,872) Unchanged	▼ 15%

Key figures of PHARMAWATCH, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMAWATCH?

What happened at PHARMAWATCH in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: loss of € 30,674 (▼ € 65,707 vs 2024). filed late Source: NBB ↗
2025 Didier Laeckmann became a director. NBB
Jan 27, 2014 Start of the company according to the CBE. KBO

In short

From € 61,886 profit in 2022 to € 30,674 loss in 2025.

Paid € 56,854 in corporate taxes since 2022.

Best year ever: 2022, with € 61,886 profit.

Original PDFs at the National Bank ↗

A new publication or filing at PHARMAWATCH? We notify you, reason included.

Follow PHARMAWATCH

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Didier Laeckmann

PHARMAWATCH

Behind PHARMAWATCH is Didier Laeckmann.

See the full network in the app

Directors

According to the 2025 annual accounts

Didier Laeckmann

Director

since 2025

Establishments

Establishment units

Physical locations of this company

Registered office

Hondsstraat 19 box 4

3700 Tongeren-Borgloon

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Vereniging van Mede-eigenaars Residentie DOMUS BELGAE te 3700 Tongeren, Hondsstraat 19

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0544.921.155

VAT number

BE 0544.921.155

Registered office

Hondsstraat 19 bus 4, 3700 Tongeren-Borgloon

Names & denominations

PHARMAWATCH

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

27 January 2014

Peppol

Active · Active since 26 Dec 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMAWATCH

Financials

What happened to PHARMAWATCH?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions